I think a straight buy out is best for the JV. Sell it after the last round of assays come back. Forget about scoping and pfs updates for HPAL. Let the buyers do that.
RNU Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
I88 Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”
